Leqembi Wins Full FDA Approval as First Anti-Amyloid Antibody for Alzheimer’s

Thursday, Eisai and Biogen’s Leqembi also became the first disease-modifying treatment for Alzheimer’s to win traditional approval. CMS coverage is expected to begin immediately.